The Investor Relations website contains information about Evoke Pharma, Inc.'s business for stockholders, potential investors, and financial analysts.
Investor Relations. Overview · Press Releases ... (NASDAQ: EVOK), a specialty ... Evoke Pharma Reports Third Quarter 2023 Financial Results.
Investor Relations. Overview · Press Releases · SEC ... Evoke Pharma 4th Quarter and Full Year 2023 Earnings Webcast ... Evoke Pharma to Present at Rodman & Renshaw ...
Missing: evok | Show results with:evok
People also ask
What does evoke Pharma do?
Where is Evoke Pharma located?
Apr 10, 2024, ARS. An annual report to security holders ; Apr 10, 2024, DEF 14A. Official notification to shareholders of matters to be ...
Our mission is to identify, invest, and help build businesses that are seeking solutions to some of the hardest challenges in the climate technology sector.
Missing: investor | Show results with:investor
This information can be used by investors to verify and understand the financial position of the company. Many, but not all SEC filings are available in the ...
Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI) diseases.
Evoke Pharma, Inc. (EVOK) Q4 2023 Earnings Call Transcript
seekingalpha.com › article › 4678378-ev...
Mar 14, 2024 · (NASDAQ:EVOK) Q4 2023 Results Conference Call March 14, 2024 4:30 PM ET. Company Participants. Daniel Kontoh-Boateng - Investor Relations
Evoke Pharma, Inc. (US:EVOK) has 19 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).